Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Clinical Trials Identifier : NCT03811561 Trial Name : A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS) Diabetes type : Adults with type 2 diabetes Trial Sponsor : Novo Nordisk Why does this trial matter
What it's best known for Sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management, both FDA-approved
Include the beyond-use date of your current vial
GLP-1s agonists are a class of medications that help manage blood sugar levels in people with Type 2 diabetes and can also help treat obesity
Clinically significant safety concerns include heart rate elevation, risk of hypoglycaemia when combined with insulin or sulfonylureas, delayed gastric emptying, and a class-relevant caution regarding thyroid C-cell tumours
In one configuration, the assay reagents measure total glutathione using a reducing agent that converts all the glutathione, GSH and GSSG in a cell lysate to the reduced form, GSH
US$ 27.58
US$ 29.63
US$ 29.75
US$ 29.65
US$ 20.72
US$ 22.93
